S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.92 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.39 (+1.12%)
T   17.62 (+0.40%)
F   13.29 (+1.76%)
MU   117.81 (-1.12%)
CGC   8.54 (-10.58%)
GE   175.85 (-2.37%)
DIS   122.42 (+1.19%)
AMC   3.72 (-14.29%)
PFE   27.80 (+0.07%)
PYPL   66.99 (+0.63%)
XOM   116.20 (+1.07%)
OTCMKTS:ATBPF

Antibe Therapeutics (ATBPF) Stock Price, News & Analysis

$0.32
-0.01 (-3.05%)
(As of 03/27/2024 ET)
Today's Range
$0.32
$0.32
50-Day Range
$0.31
$0.78
52-Week Range
$0.24
$0.89
Volume
750 shs
Average Volume
34,994 shs
Market Capitalization
$16.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ATBPF stock logo

About Antibe Therapeutics Stock (OTCMKTS:ATBPF)

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

ATBPF Stock Price History

ATBPF Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Antibe Therapeutics reports Q2 results
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Antibe Announces Results of 2023 Annual Meeting
Antibe Therapeutics Inc. (ATBPF)
Maxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)
Antibe Provides Development Update for Otenaproxesul
Antibe Announces Results of 2022 Annual Meeting
See More Headlines
Receive ATBPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ATBPF
CIK
N/A
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

Net Income
$-14,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.67 million
Book Value
$0.58 per share

Miscellaneous

Free Float
48,213,000
Market Cap
$16.85 million
Optionable
Not Optionable
Beta
0.57
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Daniel Marcel Legault J.D. (Age 66)
    L.L.B., President, CEO, Secretary & Director
    Comp: $548.19k
  • Mr. Alain Wilson M.B.A.
    MBA, Chief Financial Officer
  • Mr. Scott Curtis C.F.A.
    M.Eng, Chief Operating Officer
  • Dr. David James Vaughan Ph.D. (Age 74)
    Chief Development Officer
    Comp: $299.31k
  • Dr. Joseph Stauffer D.O. (Age 58)
    M.B.A., Chief Medical Officer
    Comp: $817.09k
  • Dr. Ana Stegic
    Executive Director of Clinical Operations
  • Ms. Christina Cameron B.B.A.
    Vice President of Investor Relations
  • Mr. Philip Stern
    Vice President of Communications

ATBPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATBPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATBPF, but not buy additional shares or sell existing shares.
View ATBPF analyst ratings
or view top-rated stocks.

How have ATBPF shares performed in 2024?

Antibe Therapeutics' stock was trading at $0.6820 at the beginning of 2024. Since then, ATBPF stock has decreased by 53.3% and is now trading at $0.3183.
View the best growth stocks for 2024 here
.

Are investors shorting Antibe Therapeutics?

Antibe Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 8,900 shares, a decrease of 73.1% from the February 29th total of 33,100 shares. Based on an average daily trading volume, of 88,700 shares, the short-interest ratio is currently 0.1 days.
View Antibe Therapeutics' Short Interest
.

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) issued its earnings results on Wednesday, February, 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03.

How do I buy shares of Antibe Therapeutics?

Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ATBPF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners